Manchester Cancer

Guidelines for the diagnosis and treatment of myeloproliferative neoplasms including:

Polycythaemia vera

Essential thrombocythaemia

and

Myelofibrosis

Rowena Thomas-Dewing
Muhammad Saif
Rachel Brown
Tim Somervaille

October 2019

Index

1.   Polycythaemia vera   **Rowena Thomas-Dewing**

Polycythaemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterised predominantly by erythrocytosis. It is associated with *JAK2* mutations (V617F or exon 12) in almost all cases. Sixty percent of PV patients are >60 years of age and 10% are <40 years of age. The incidence is the same in males and females.

Diagnostic criteria

The *JAK2* V617F mutation is found in 95% of WHO defined PV, and a further 2 to 4% of patients harbour mutations in exon 12. In patients with erythrocytosis without either of these mutations, secondary or other causes of erythrocytosis should be sought.

Revised WHO diagnostic criteria (2016) for polycythaemia vera

Diagnosis requires all 3 major criteria or the first 2 major criteria and the minor criterion[*]

MAJOR
(i)   Haemoglobin >16.5g/dl in men, >16.0 g/dl in women or haematocrit >49% in men, >48% in women or increased red cell mass >25% above mean normal predicted value.
(ii)   Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) including prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic, mature megakaryocytes (differences in size)
(iii)   Presence of *JAK2* V617F mutation or *JAK2* exon 12 mutation

MINOR
(i)   serum erythropoietin level below the reference range for normal.

[*]Criterion number 2 (bone marrow biopsy) may not be required in cases with sustained absolute erythrocytosis: haemoglobin levels >18.5g/dL in men (haematocrit, 55.5%) or 16.6g/dL in women (haematocrit, 49.5%) if major criterion 3 and minor criterion are present. However, initial myelofibrosis (present in up to 20% of patients) can only be detected by performing a BM biopsy; this finding may predict a more rapid progression to overt myelofibrosis (post-PV MF).

Clinical and pathological features

Erythrocytosis may be an incidental finding or discovered during investigation of non-specific symptoms (e.g. pruritus often after a warm bath or shower, headache, tinnitus, blurred vision, abdominal discomfort, fatigue) or after an episode of gout. In 10 to 15% of cases, the diagnosis of PV occurs with, or shortly after a thrombotic event. A detailed history including cardiovascular risk factors, past medical history and concurrent medications is essential to provide optimal advice on lifestyle modifications. Physical examination may reveal a ruddy complexion or palpable splenomegaly (found in 25-40% of cases).

Investigations

FBC, renal and liver function tests, *JAK2* mutation. Consider performing serum ferritin, oxygen saturations, serum erythropoietin level, abdominal ultrasound and bone marrow aspirate, trephine biopsy and cytogenetic studies.

Patients lacking a mutation in *JAK2* should be investigated for secondary causes of polycythaemia.

Prognostic factors for risk-adapted therapy in PV

Risk factors for thrombosis

Age >65 years and prior history of thrombosis

The Efficacy and Safety of Low-dose Aspirin in Polycythaemia Vera (ECLAP) study reported that patients younger than 65 years without prior thrombosis have an incidence of thrombosis of 2.5 per 100 persons/year. Those older than 65 years or with prior thrombosis have an incidence of 5.0 per 100 persons/year. Those older than 65 years with prior thrombosis have an incidence of 10.9 per 100 persons/year.

Cardiovascular risk factors (smoking, hypertension, hypercholesterolemia, diabetes, obesity) should be addressed and corrected but are not formally considered during risk stratification.

Leukocytosis and *JAK2* mutant allele burden are also not formally considered during risk stratification.

Risk factors for disease progression

Approximately 10% of PV patients evolve into post-PV myelofibrosis (MF). MF evolution is difficult to predict. Leukocyte count >15 x10^9/L, *JAK2* mutant allele burden >50% and bone marrow fibrosis have all been associated with a higher risk of MF evolution.

Fewer than 5% of PV patients progress to AML.

Risk factors for survival

A prognostic model for overall survival has been developed based on age, leukocytosis and prior venous thrombosis. It separates patients into three groups with median survivals of 28, 19 and 11 years respectively (Tefferi et al., 2013).

Treatment

The aim of therapy is to reduce the risk of thrombosis and to provide symptom relief where required. There is no evidence to date for any treatment that alters the natural history of the disease.

Table 1 Criteria for risk stratification in patients with PV and risk-adapted therapy**

Risk category	Risk variables	Therapy
Low	Age <65 years old without history of thrombosis	Venesection to haematocrit of ≤45%, aspirin and optimisation of cardiovascular risk factors
High	Age ≥65 years old and/or with history of thrombosis	Cytoreduction±venesection to haematocrit of ≤45%, aspirin* and optimisation of cardiovascular risk factors

* Or, depending on anticipated risk of future thrombosis, oral anticoagulation
** Recent BCSH guidelines recommend age 65 as cut off for low versus high risk PV in absence of thrombosis; other international guidelines or opinion pieces continue with age 60.

(i) Optimisation of cardiovascular risk factors

Stop smoking, recommend exercise programme and dietary advice where appropriate, and optimal management of hypertension or diabetes where present. Consider making use of a cardiovascular disease risk assessment tool (e.g. QRISK2) and statin therapy.

(ii) Antiplatelet therapy

Aspirin 75mg OD unless contraindicated. Clopidogrel is an alternative.

The ECLAP study demonstrated that the risk of the combined end point of non-fatal myocardial infarction, non-fatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes was significantly reduced by low dose aspirin 100mg/day (relative risk 0.40, p = 0.03)

(iii) Venesection

Patients should receive venesection unless contraindicated (±concomitant fluid replacement) to maintain the haematocrit at ≤45%. The PVSG-01 study established venesection as first line therapy in PV.

(iv) Cytoreductive therapy

Cytoreductive therapy should be considered in high risk patients, those who tolerate venesection poorly, or in patients with symptomatic splenomegaly or thrombocytosis.

a. Hydroxycarbamide

Recommended first line therapy for cytoreduction. No controlled study has firmly demonstrated hydroxycarbamide as being leukaemogenic in PV.

b. Conventional** or pegylated Interferon-alpha

Interferon is non-leukaemogenic and therefore all younger patients (≤40yr) should be offered a trial of therapy. However, the side effect profile leads to discontinuation in 20-40% of patients.

(October 2019: ** Roferon and Intron-A have recently been withdrawn from the market for commercial reasons)

c. Anagrelide

May be effective in managing those PV patients with concomitant thrombocytosis but its side effect profile may be difficult for some patients to tolerate.

d. Radioactive phosphorus** and intermittent lose dose busulphan have been used in the past with caution in older patients intolerant or resistant to hydroxycarbamide. Regarding busulphan, some concerns exist that it may enhance disease transformation, although an extensive analysis from the Mayo clinic found no evidence in 1500 patients of enhanced leukaemogenicity (Tefferi & Barbui, 2019).

(October 2019: ** ^{32}P has recently been withdrawn from the market for commercial reasons)

e. Ruxolitinib. Although not available on the NHS, the JAK2 inhibitor ruxolitinib is effective therapy for poorly controlled PV patients, or those who are resistant to or intolerant of hydroxycarbamide. It is particularly effective for associated constitutional symptoms such as pruritus and sweats. In the RESPONSE trial there was improved haematocrit control, spleen size reduction and reduced total symptom score by comparison with best available therapy. The MAJIC trial comparing ruxolitinib to best available therapy in PV patients resistant to or intolerant of hydroxycarbamide has now completed recruitment in the UK and results are awaited.

f. PV patients who are intolerant or resistant to hydroxycarbamide should be considered for referral for clinical trial options at major centres, should there be availability.

Special situations

Splanchnic vein thrombosis (SVT)

PV is a frequent underlying cause of SVT that includes Budd-Chiari syndrome, mesenteric, splenic, or portal vein thrombosis. Up to 70% of SVT is developed prior to MPN diagnosis. The estimated prevalence of MPN in patients with Budd-Chiari syndrome and portal vein thrombosis is 30-50% and 15-30% respectively. Young women are preferentially affected. JAK2 V617F mutation is present in 50-60% of Budd-Chiari syndrome and 20-40% of portal vein thrombosis. It is important to note that the peripheral blood count may be normal due to haemodilution (erthrocytosis is masked by an expanded volume of plasma). The bone marrow biopsy may not be pathognomonic.

Management should be joint with an expert hepatologist. Lifelong anticoagulation should be considered, although its risks need to be weighed in the presence of portal hypertension and oesophageal varices. Cytoreductive therapy to normalise the full blood count is recommended. Surgical treatment includes transjugular intrahepatic portosystemic shunt, angioplasty with or without stenting, surgical shunts, and liver transplantation.

Pruritus

No reliably effective therapies are currently available on the NHS. Antihistamines are often ineffective, although can on occasion be beneficial: chlorpheniramine, fexofenadine, loratidine or cetirizine could all be tried – anecdotal evidence is that sometimes there is a response with one but not necessarily all. In selected cases, phototherapy using psoralen and ultraviolet A light may be successful, as may interferon. Ruxolitinib is generally very effective if available.

Selected references

Arber D, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukaemia. Blood. 2016; 127(20): 2391-2405.

Barbui T, Barosi G, Birgegard G et al. Philadelphia negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European Leukemia Net. J Clin Oncol. 2011; 29 (6): 761-770.

Bench AJ, White HE, Foroni L et al. British Committee for Standards in Haematology. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol. 2013. 160(1):25-34.

Ellis MH, Lavi N, Vannucchi A, Harrison C. Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey. Thromb Res. 2014; 134(2): 251-254.

Kiladjian JJ, Chomienne C, Fenaux P. Interferon–alpha therapy in *BCR-ABL*-negative myeloproliferative neoplasms. Leukemia. 2008; 22(11):1990-1998.

Landolfi R, Marchioli R, Kutti J et al. European Collaboration on Low-Dose Aspirin in Polycythaemia vera Investigators. Efficacy and safety of low-dose aspirin in polycythaemia vera. N Engl J Med. 2004; 350(2):114-124.

Marchioli R, Finazzi G, Landolfi R et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005; 23(10):2224-2232.

McMullin MF, Harrison C, Ali S et al. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. Br J Haematol. 2018; 184, 176-191.

McMullin MF, Bareford D, Campbell P et al. British Committee for Standards in Haematology. Guidelines for the diagnosis, investigation and management of polycythaemia/ erythrocytosis. Br J Haematol. 2005; 130, 174-195.

McMullin MF, Reilly JT, Campbell P et al; National Cancer Research Institute, Myeloproliferative Disorder Subgroup. British Committee for Standards in Haematology. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol. 2007; 138(6):821-822.

Mesa RA, Niblack J, Wadleigh M et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet- based survey of 1179 MPD patients. Cancer. 2007; 109(1):68-76.

Passamonti F. How I treat polycythaemia vera. Blood. 2012; 120(2):275-284.

Passamonti F, Rumi E, Caramella M et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008; 11(7):3383-3387.

Passamonti F, Rumi E, Pietra d et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010; 24(9):1574-1579.

Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol. 2011;86(8):668-676.

Smalberg JH, Arends LR, Valla DC et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012; 120 (25):4921-4928.

Spivak JL, Moliterno AR, Silver RT et al. Case15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2. N Engl J Med. 2006; 355(7): 737, author reply 738.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Reaserch on Cancer; 2008.

Tefferi A, Rumi E, Finazzi G et al. Survival and prognosis among 1545 patients with contemporary polycythaemia vera: an international study. Leukemia. 2013; 27(9):1874-1881.

Tefferi A, Barbui, T. Polycythaemia vera and essential thrombocythaemia: 2019 update on diagnosis, risk-stratification and management. American Journal of Hematology 94:133-143.

Vannucchi AM. How I treat polycythaemia vera. Blood. 2014; 124(22): 3212-3220

Vainchenker W, Delhommeau F, Constantinescu SN et al. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011; 118(7):1723-1735.

Verstovsek S, KantarjianH, Mesa RA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor in myelofibrosis. N Engl J Med. 2010; 363(12):1117-1127.

2. Essential thrombocythaemia   Muhammad Saif & Rachel Brown

Essential thrombocythaemia (ET) is a clonal myeloproliferative neoplasm characterised by thrombocytosis, megakaryocytic hyperplasia, absence of the Philadelphia chromosome and no evidence of other myeloid disorders such as polycythemia vera or primary myelofibrosis. Mutations in JAK2 (V617F), CALR or MPL (W515K/L) may be found in approximately 50%, 30% and 5% of patients respectively. Recent data suggest that these molecular abnormalities may be associated with distinct clinical characteristics and may also have prognostic significance.

Diagnostic criteria

The British Committee for Standards in Haematology has provided diagnostic criteria for ET modified from the WHO criteria. These have recently been updated to incorporate CALR mutation analysis.

To diagnose ET there is a requirement to demonstrate either A1-A3 or A1 + A3–A5:

A1   Sustained platelet count >450 × 10^9/l
A2   Presence of an acquired pathogenetic mutation (e.g. in the JAK2, MPL or CALR genes)
A3   No other myeloid malignancy, especially PV, PMF, CML or MDS
A4   No reactive cause for thrombocytosis and normal iron stores
A5   Bone marrow aspirate and trephine biopsy showing increased megakaryocyte numbers displaying a spectrum of morphology with predominant large megakaryocytes with hyperlobated nuclei and abundant cytoplasm. Reticulin is generally not increased (grades 0–2/4 or grade 0/3)

Clinical presentation and pathological features

The median age of presentation is 60 years and thrombosis is the most common complication. Advanced age and prior history of thrombosis are the strongest predictors for future thrombosis. Other factors, such as hypertension, diabetes, dyslipidemia, smoking, leucocytosis and thrombophilia may also increase the risk of thrombosis. The correlation between thrombocytosis level and risk of future thrombosis is less clear. Indeed high platelet count may be associated with bleeding due to acquired von Willebrand Disease.

Investigations

FBC, renal and liver function tests, ferritin, *JAK2* mutation. If *JAK2* mutation negative, consider performing *CALR* or *MPL* mutation analysis. Consider bone marrow aspirate, trephine biopsy and cytogenetic studies.

Risk Stratification

As per European Leukemia Network recommendations and BCSH guidelines, patients may be risk stratified as follows:

HIGH RISK

≥60 years of age
OR have had an ET-related thrombotic or haemorrhagic event
OR who have a platelet count of >1500 × 10^9/l

Additional high risk features include: any history of ischemia, thrombosis or embolic events, microvascular abnormalities (e.g. erythromelalgia), presence of hypertension or diabetes.

LOW RISK

<40 years of age with no high risk features

INTERMEDIATE RISK

40–60 years with no high risk features

A recent study of CALR-mutated ET patients aged <60 without a history of thrombosis demonstrated that aspirin (by comparison with observation alone) did not affect thrombosis rate but did increase bleeding. More generally, it has become increasingly apparent that the presence of a JAK2 mutation leads to increased risk of thrombosis by comparison with the presence of CALR or other mutations. This has led to a revision of risk stratification by some authorities (e.g. Tefferi & Barbui, 2019):

HIGH RISK

>60 years of age with a JAK2 mutation
OR history of thrombosis

INTERMEDIATE RISK

No history of thrombosis
>60 years of age without a JAK2 mutation

LOW RISK

No history of thrombosis
≤60 years of age with a JAK2 mutation

VERY LOW RISK

No history of thrombosis
≤60 years of age without a JAK2 mutation

Management

Modification of risk factors

All patients should be screened for risk factors for thrombosis such as hyperlipidemia, diabetes, hypertension and smoking and managed appropriately. Consider making use of a cardiovascular disease risk assessment tool (e.g. QRISK2) and statin therapy.

Antiplatelet therapy

Aspirin reduces the incidence of cardiovascular and thrombotic events and has historically been recommended for all patients with ET unless contraindicated. Clopidogrel is an alternative in patients allergic to aspirin or those with peptic ulcer disease. Newer recommendations (e.g. Tefferi & Barbui, 2019) suggest that very low risk patients without cardiovascular risk factors can safely be managed by observation alone without antiplatelet therapy.

In view of the abnormal megakaryopoiesis in ET the anti-platelet activity of aspirin may not last a full 24 hours due to faster renewal of COX1. Recent in vitro studies suggest that twice daily aspirin may provide more effective anti-thombotic activity for higher risk patients and this could be considered in those with a JAK2 mutation or with a history of arterial thrombosis (although a formal clinical trial has not been conducted).

Indications for cytoreductive therapy

High risk patients should be offered cytoreduction aiming to reduce the platelet count to the normal range. Low and intermediate risk patients can be observed (on aspirin, once or twice daily) and considered for cytoreductive therapy where high risk features develop. Some intermediate risk patients with high cardiovascular risk should be considered for cytoreductive therapy.

In patients who are refractory to or intolerant of cytoreductive therapy, consider relaxing the platelet target to <600x10^9/L or change medication.

Hydroxycarbamide

Hydroxycarbamide reduces thrombotic risk in high risk ET patients and is first line therapy for most high risk ET patients. Younger patients (e.g. ≤40 years) should be offered a trial of interferon therapy.

Anagrelide

Anagrelide is an option for second line therapy in hydroxycarbamide resistant or intolerant patients. Combination treatment with hydroxycarbamide and anagrelide has also been successfully used. Anagrelide provides inferior thrombosis risk reduction compared with hydroxycarbamide. For those patients taking anagrelide monitoring by bone marrow examination every 2-3 years is essential to rule out the development of marrow fibrosis, a recognized side effect of anagrelide therapy.

Interferon alpha

Interferon is effective in reducing the platelet count in ET as well as *JAK2* allelic burden. A recent study has demonstrated the efficacy of pegylated interferon in ET patients who were previously refractory or intolerant to hydroxycarbamide (Yacoube et al., 2019).

Younger patients (e.g. ≤40 years), or those contemplating pregnancy, should be offered a trial of interferon therapy. Conventional interferon can be difficult to tolerate due to its side effects and in various trials about 30% of patients discontinued its use due to intolerance (OCT 2019 – Roferon and Intron-A were recently withdrawn from the market for commercial reasons). The toxicity profile of pegylated interferon is not necessarily superior to recombinant interferon but it is more convenient to administer.

Other agents

Radioactive phosphorus** and intermittent lose dose busulphan have been used in the past with caution in older patients intolerant or resistant to hydroxycarbamide. Regarding busulphan, some concerns exist that it may enhance disease transformation, although an extensive analysis from the Mayo clinic found no evidence in 1500 patients of enhanced leukaemogenicity (Tefferi & Barbui, 2019).

(October 2019: ** 32P has recently been withdrawn from the market for commercial reasons)

JAK2 inhibitors

Ruxolitinib has been recently evaluated in clinical trials in ET but results from the MAJIC study demonstrated it was not superior to best available therapy in patients resistant to or intolerant of hydroxycarbamide. It is not available on the NHS for this indication.

Selected references

Assaf C, Obbergh F, Billiet J et al Analysis of Phenotype and Outcome in Essential Thrombocythemia with CALR or JAK2 mutations by Haematologica 2015 [Epub ahead of print]

Antonioli E, Guglielmelli P, Poli G, et al. (2008) Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 93:41–48.

Arellano-Rodrigo A, Alvarez-Larrán A, Reverter JC, et al.(2009) Platelet turnover, coagulation factors and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol 84:102–108.

Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008;112(1):141-149.

Barbui T, Barosi G, Birgegard G, et al. (2011) Philadelphia–negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761–770.

Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061

Campbell PJ, Scott LM, Buck G, et al. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945–1953.

Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999;13(2):150-154.

Carobbio A,Finazzi G,Antonioli E,et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008;112(8):3135-3137.

Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332(17):1132-1136.

Cortelazzo S,Viero P, Finazzi G,D'Emilio A, Rodeghiero F,Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8(3):556-562.

Cervantes F, Arellano-Rodrigo E, and Álvarez-Larrán A(2009) Blood cell activation in the myeloproliferative neoplasms. Haematologica 94:1484–1488.

Falanga A, Marchetti M, Vignoli A, et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007; 35:702–711.

Harrison C, David Bareford D, Butt N, Campbell P, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis 2010;149(3):352-375.

Harrison CN, Campbell PJ,Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353(1):33-45.

Harrison C, Butt N, Campbell P et al Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia, British Journal of Haematology, 2014, 167, 418–438.

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 N Engl J Med. 2013;369(25):2391-405.

Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.

Pardanani AD, Levine RL, Lasho T, et al.(2006) MPL mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108:3472–3476.

Panagiota v, Thol F, Markus B, et al. Outcoem fo Jak2/MPL.CALR after allogeneic stem cell transplantation, paper presented at European Haematology Association annual meeting June 12-15, 2014, Milan Italy.

Tefferi A, Barbui, T. Polycythaemia vera and essential thrombocythaemia: 2019 update on diagnosis, risk-stratification and management. American Journal of Hematology 94:133-143.

Vannucchi AM, Antonioli E, Gugielmelli P,et al.(2008) Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 112:844–847.

Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea. Blood. 2019 Sep 12. [Epub ahead of print]

3.   Myelofibrosis   Tim Somervaille

These guidelines will address the diagnosis, prognosis and treatment of patients with

(i)   Primary myelofibrosis (PMF);
(ii)   Post-essential thrombocythaemia myelofibrosis (post-ET MF); and
(iii)   Post-polycythaemic myelofibrosis (post-PV MF).

The many other conditions associated with reticulin or collagen fibrosis of the bone marrow will not be discussed further.

Primary myelofibrosis

PMF is a clonal neoplasm associated with an abnormal expansion predominantly of megakaryocyte and granulocyte lineages which leads to bone marrow fibrosis and extramedullary haematopoiesis. Evolution of the disease may be progressive with an initial hypercellular phase with minimal fibrosis (up to 30% of patients) followed over time by increasing fibrosis and osteosclerosis. Its incidence approximates to 1 case per 100,000/year with no sex bias and a median age of presentation of around 60.

Diagnostic criteria (World Health Organisation 2016)

Diagnosis requires all three major and at least 1 minor criterion:

MAJOR

(i)   Presence of megakaryocyte proliferation and atypia (small to large megakaryocytes with an aberrant nuclear/cytoplasmic ration and hyperchromatic, bulbous, or irregularly folded nuclei and dense clustering), usually accompanied by either reticulin and/or collagen fibrosis Grades 2 or 3; OR in the absence of significant reticulin fibrosis, the megakaryocyte changes must be accompanied by an increased bone marrow cellularity characterised by granulocytic proliferation and often decreased erythropoiesis (i.e. prefibrotic cellular phase disease)**

(ii)   Not meeting WHO criteria for Essential Thrombocythaemia, polycythaemia vera, *BCR-ABL1*[+] chronic myeloid leukaemia, myelodysplastic syndrome or other myeloid neoplasm

(iii)   Demonstration of *JAK2* V617F mutation or other clonal marker such as *MPL* W515K/L or *CALR* mutation[a]; OR in the absence of a clonal marker, no evidence that the bone marrow fibrosis or other changes are secondary to infection, autoimmune disorder or other chronic inflammatory conditions, hairy cell leukaemia or other lymphoid neoplasm, metastatic malignancy or toxic myelopathies

MINOR: (confirmed in 2 consecutive determinations)

(i)   Leucoerythroblastosis

(ii)   Increase in serum lactate dehydrogenase (LDH) level

(iii)   Anaemia not attributed to a comorbid condition

(iv)   Leukocytosis $\geq 11 \times 10^9$/L

(v)   Palpable splenomegaly

Clinical and pathological features

Up to 30% of patients may be asymptomatic at diagnosis, with the condition picked up on a routine blood count (e.g. anaemia, thrombocytosis), chemistry screen (e.g. raised LDH) or examination (e.g. splenomegaly). Others may complain of constitutional symptoms, such as fatigue, dyspnoea, weight loss, night sweats, low-grade fever and pruritus (related to raised levels of proinflammatory cytokines); symptoms related to gout; or symptoms related to splenomegaly, such as early satiety and left upper quadrant discomfort.

Up to 90% of patients exhibit splenomegaly and 50% hepatomegaly.

Investigations

Baseline investigations include blood count, blood film (often shows tear drop poikilocytes), renal and liver function tests, LDH, haematinics and *JAK2* V617F mutation status (found in ~50% of patients). Consider *BCR-ABL* analysis if trephine biopsy is atypical, and exclusion of *PDGFRA/B* rearrangements where eosinophilia is noted. Extended testing for a panel of myeloid mutations is often appropriate to identify patients with a poorer longer term prognosis (i.e. those with mutations in ASXL1, EZH2, IDH1/IDH2 etc.).

Careful examination of megakaryocyte morphology is essential to distinguish prefibrotic PMF with accompanying thrombocytosis from essential thrombocythaemia. This is because the former mostly evolves in to overt fibrotic/sclerotic PMF whereas the latter mostly does not. Megakaryocytes exhibit significantly greater atypia in the former versus the latter condition.

Karyotype analysis recurrently indicates lesions such as del(13)(q12-22), der(6)t(1;6)(q21-23;p21.3), del(20q), partial trisomy 1q, trisomy 8 and trisomy 9.

The presence of 10-19% CD34[+] blasts indicates an accelerated phase of the disease. The presence of 20% or more blasts indicates acute myeloid leukaemia.

Post-polycythaemia myelofibrosis

During the later phases of polycythaemia vera the disease may progress to post-polycythaemia myelofibrosis (post-PV MF) in approximately 20% of cases. The red cell mass may normalise and then contract, the blood film may show a leucoerythroblastic picture with tear drop poikilocytes and splenomegaly may develop. The bone marrow may be hypocellular with prominent megakaryocyte atypia and reticulin/collagen fibrosis. Blasts are typically less than 10%; a higher frequency may indicate an accelerated phase of the disease.

Diagnostic criteria for post-polycythaemia myelofibrosis

REQUIRED

    (i)   Documentation of a previous diagnosis of PV (see section 1 above)

    (ii)   Bone marrow fibrosis grade 2-3

ADDITIONAL CRITERIA (two required)

    (i)   Anaemia or sustained loss of either phlebotomy (in the absence of cytoreductive therapy) or requirement for cytoreduction treatment for erythrocytosis

    (ii)   Leucoerythroblastosis

    (iii)   Increasing splenomegaly defined as either an increase in palpable splenomegaly of > 5cm from baseline, or the appearance of newly palpable splenomegaly

    (iv)   Development of >1 of 3 constitutional symptoms: >10% weight loss in six months, night sweats, unexplained fever >37.5C

Post-essential thrombocythaemia myelofibrosis

ET is typically an indolent disorder characterised by long symptom-free periods interrupted by occasional haemorrhage or thrombosis. Evolution to myelofibrosis in ET is uncommon.

It is of note that the early stages of primary myelofibrosis may mimic ET. Careful evaluation of the BM biopsy is essential to distinguish the two conditions which have quite distinct prognoses.

Diagnostic criteria for post-essential thrombocythaemia myelofibrosis

REQUIRED

   (i)   Documentation of a previous diagnosis of ET (section 1 above)

   (ii)   Bone marrow fibrosis grade 2-3

ADDITIONAL CRITERIA (two required)

   (i)   Anaemia or > 2g/dl decrease from baseline haemoglobin levels

   (ii)   Leucoerythroblastosis

   (iii)   Increasing splenomegaly defined as either an increase in palpable splenomegaly of > 5cm from baseline, or the appearance of newly palpable splenomegaly

   (iv)   Increased LDH above baseline level

   (v)   Development of >1 of 3 constitutional symptoms: >10% weight loss in six months, night sweats, unexplained fever >37.5C

Prognostic scoring systems

Note that these prognostic scoring systems are derived from studies which only included patients with PMF, and excluded those with post-PRV or post-ET MF. Caution should be used in the application of these risk stratifications to patients with post-PRV or post-ET MF.

1) International Working Group of Myelofibrosis Research and Treatment

Score 1 for each of the following at diagnosis:

(i)   age ≥ 65
(ii)   presence of constitutional symptoms
(iii)   haemoglobin ≤ 10g/dl
(iv)   WBC ≥ 25x10^9/l
(v)   Blood blasts ≥ 1%

Risk group	Score	Median survival (months, 95% CI)
Low	0	135 (117-181)
Intermediate-1	1	95 (79-114)
Intermediate-2	2	48 (43-59)
High	≥ 3	27 (23-31)

Webtool: http://www.siematologia.it/LG/IWG/IWG.htm

2) Dynamic International Prognostic Scoring System (DIPSS) for PMF

This is suitable for assessment of prognosis at any time during the clinical course. The acquisition of transfusion dependence (not induced by therapy) is a particularly adverse prognostic feature.

Prognostic variable	Score 0	Score 1	Score 2
Age, yrs	≤ 65	≥ 65	
WBC, x10^9/l	≤ 25	≥ 25	
Haemoglobin, g/dl	≥ 10		≤ 10
Blood blasts, %	≤ 1	≥ 1	
Constitutional symptoms	No	Yes	

Risk group	Score	Median survival (years)
Low	0	not reached
Intermediate-1	1-2	14.2
Intermediate-2	3-4	4
High	5-6	1.5

Webtool: https://qxmd.com/calculate/calculator_187/dipss-prognosis-in-myelofibrosis

3) Age adjusted DIPPS for PMF, for patients younger than 65

This is particularly useful for assessment of candidates for allogeneic transplantation.

Prognostic variable	Score 0	Score 1	Score 2
WBC, x10^9/l	≤ 25	≥ 25	
Haemoglobin, g/dl	≥ 10		≤ 10
Blood blasts, %	≤ 1		≥ 1
Constitutional symptoms	No		Yes

Risk group	Score	Median survival (years)
Low	0	not reached
Intermediate-1	1-2	9.8
Intermediate-2	3-4	4.8
High	More than 4	2.3

Webtool: https://qxmd.com/calculate/calculator_315/dipss-plus-score-for-prognosis-in-myelofibrosis

4) MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis

Where information from mutation of karyotype analyses is available, consider use of the MIPSS70 scoring system: http://www.mipss70score.it/

Note that presence of thrombocytopaenia, anaemia, adverse cytogenetics or adverse mutations can substantially alter a patient's risk score according to which of the scoring systems is used.

Treatment overview

Typically, the risk score dictates treatment.

For asymptomatic patients with **low risk** or **intermediate-1 risk** disease, there is currently no evidence to support therapeutic intervention. These patients should be followed on a watch and wait basis, unless specific disease-associated symptoms are troublesome. Management of these is discussed below.

For patients with **high risk** or **intermediate-2 risk** disease, the choice of management strategies lies between allogeneic transplantation and palliation. The only curative treatment for PMF is allogeneic bone marrow transplantation. Non-transplant therapies are palliative. Emerging data suggest treatment with JAK2 inhibitors may provide a survival benefit.

Allogeneic bone marrow transplantation

The BCSH recommendations for allogeneic transplantation in myelofibrosis are as follows and apply to those considered fit enough to undergo the procedure, who have an estimated life expectancy of less than five years and an available sibling or matched unrelated donor:

Age <45, IPSS INT-2 or high risk – consider for myeloablative BMT (e.g. Bu/Cy or Cy/TBI conditioning)
Age >45, IPSS INT-2 or high risk – consider for reduced intensity BMT (e.g. Flu/TBI (2Gy), Flu/Bu/ALG)

All patients with myelofibrosis should be considered for allogeneic transplant and referred to an appropriate centre for evaluation where appropriate.

Reported 3-5 year survival rates are 30-50% for MF patients treated with allo BMT. There is variability in transplantation policies at different centres. While in the UK and elsewhere transplantation is offered to INT-2 and high risk patients, in Boston some INT-1 patients are considered and some higher risk patients are excluded (e.g. those with massive splenomegaly and a significant transfusion history) on the basis that their outcome following transplant is dismal.

The role for JAK2 inhibitors either before or following allogeneic BMT is currently unclear and under investigation.

JAK2 inhibitors

Given the recurrent mutations in JAK2 in PMF, inhibitors of this kinase have been developed and tested in clinical trials. Patients respond to therapy with a JAK2 inhibitor whether or not they have a JAK2 mutation.

The JAK2 inhibitor ruxolitinib (US FDA approved, November 2011) is effective in reducing spleen size and improving symptom score in myelofibrosis, both by comparison with placebo and by comparison with best available therapy. The COMFORT-1 and COMFORT-2 trials demonstrated that 30-40% of patients have >35% reduction in spleen volume and about half have a 50% improvement in symptom score. Anaemia and thrombocytopaenia were the most common adverse events; patients with platelet counts lower than 100×10^9/l were excluded. The drug was well tolerated. There is some evidence for a survival benefit for ruxolitinib treated patients over placebo treated patients in COMFORT-1.

Following NICE approval, ruxolitinib is available on the NHS for the treatment of symptomatic intermediate-2 or high risk primary myelofibrosis (or post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis). It is of particular value in patients with constitutional symptoms of disease or pruritus. Patients with single disease-related issues such as isolated uncomfortable splenomegaly or anaemia will likely benefit from alternative therapeutic approaches.

In view of its expense, ruxolitinib should only be prescribed where the anticipated benefits clearly outweigh the benefits to be gained from alternative therapies (se Management of Specific Issues section, below).

Other JAK2 inhibitors have not been so successful in clinical trials, but continue under some form of clinical investigation (October 2017) i.e. pacritinib, fedratinib and momelotinib. It remains unclear whether either will make it to market. Pacritinib may benefit patients with myelofibrosis who have significant thrombocytopaenia. Momelotinib may benefit patients who have significant anaemia. Fedratinib may benefit patients who are intolerant or resistant to ruxolitinib.

This is a fast-moving area of research and recommendations may continue to change over ensuing years. However, it seems likely that the majority of symptomatic intermediate-2 and high risk patients benefit (and possibly with prolonged survival) through treatment with a JAK2 inhibitor.

Wherever possible, ***patients should be considered for referral for clinical trials*** in view of the rarity of this disease and the generally poor outcomes.

Given that there have been infrequent reports of reactivation of latent and atypical infections in patients taking ruxolitinib (e.g. hepatitis B and tuberculosis), the prescriber should consider screening for these and consider use of appropriate prophylactic measures (e.g. aciclovir prophylaxis). Live vaccinations should be also be considered with caution.

Other agents and approaches

Other therapeutic modalities used in myelofibrosis include hydroxycarbamide, immunomodulatory agents (e.g. thalidomide, prednisolone), splenectomy, radiotherapy, blood transfusion, androgens and erythropoietin. These will be discussed in turn in the next section.

Management of specific issues

Complicated patients should be discussed with a specialist centre.

Splenomegaly and extramedullary haematopoiesis

Symptomatic splenomegaly in the absence of significant cytopaenias can be treated with anti-proliferative chemotherapy such as hydroxycarbamide (or ruxolitinib in the presence of concomitant constitutional symptoms). Other agents that may be effective (typical reported response rates are 5-40%) include low dose thalidomide (with or without prednisolone, and to be considered in those with significant cytopaenias) and possibly lenalidomide, low dose melphalan or busulphan.

Splenectomy can be considered in patients with drug-refractory symptomatic splenomegaly, severe hypercatabolism, severe portal hypertension, significant splenic infarction, or refractory haemolysis but is associated with significant morbidity and mortality and should only be undertaken at an experienced centre following careful pre-operative work-up. Beneficial responses to splenectomy may include loss of transfusion dependence and improvement in constitutional symptoms.

Splenic irradiation can be considered in patients with platelet counts >50 x 10^9/l who have failed drug therapy and are not candidates for splenectomy. However, it is typically associated with only a transient response and can induce significant cytopaenia, morbidity and mortality.

Low-dose radiotherapy can be considered for treatment of extramedullary haematopoiesis at other sites, and MF-related bone pain.

Anaemia

Where patients have symptomatic anaemia a trial of erythropoietin or darbopoietin is recommended. Erythropoiesis stimulating agents (ESAs) can exacerbate spleen size in those with significant splenomegaly, so caution is advised under these circumstances. ESAs are often of value in patients where ruxolitinib has induced anaemia or a transfusion requirement.

Other agents, each of which has a relatively low response rate, may also be tried:

(i) While many androgens have been tested (e.g. fluoxymesterone 10mg TDS), danazol is the first line androgen of choice, as recommended by the BCSH guidelines. Typical reported initial response rates are 30-50%, but with anticipated side effects of fluid retention, hirsutism, increased libido, derangement of LFTs and hepatic tumours. The recommended starting dose is 200mg OD, increasing to a maximum of 600-800mg per day. The response should be assessed at six months with subsequent titration down to the minimum dose required to maintain that response. LFTs should be checked regularly with a liver USS every 6-12 months. Male patients should be screened for prostate cancer (i.e. PSA) before therapy and regularly thereafter.

(ii) Thalidomide (e.g. 50mg/day) with or without prednisolone (e.g. 10-20mg/day). This should be avoided in women of child bearing age, those with neuropathy and those with diabetes or osteopaenia. Aspirin should be co-prescribed to minimise risk of thrombosis. Lenalidomide is not recommended. Pomalidomide is currently under evaluation.

Otherwise, transfusion is recommended for symptomatic anaemia, but routine iron chelation is not.

Constitutional symptoms including pruritus

These are best managed with a JAK2 inhibitor.

Minimising thrombotic risk

For patients with a platelet count >450x10^9/l, there is likely an increased thrombotic risk. Here treatment with hydroxycarbamide (or a JAK2 inhibitor where concomitant constitutional symptoms are present) and aspirin is warranted, together with modification of cardiovascular risk factors (e.g. control blood pressure, advice to stop smoking, treat hypercholesterolaemia, and optimise diabetic control). Consider making use of a cardiovascular disease risk assessment tool (e.g. QRISK2) and statin therapy.

Anagrelide should be used with considerable caution given its association with bone marrow fibrosis.

Use of interferon in MF has been associated with high rates of toxicity; however some small studies have reported some benefit. It is recommended to use IFN only in early disease with proliferative features.

References

Arber D, Orazi A, Hasserjian R,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukaemia. Blood. 2016; 127(20): 2391-2405.

Bacigalupo, A., Soraru, M., Dominietto, A., Pozzi, S., Geroldi, S., Van Lint, M. T., Ibatici, A., Raiola, A. M., Frassoni, F., De Stefano, F*., et al.* (2010). Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant *45*, 458-463.

Ballen, K. (2012). How to manage the transplant question in myelofibrosis. Blood Cancer J *2*, e59.

Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J. L., Barosi, G*., et al.* (2009). New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood *113*, 2895-2901.

Harrison, C., Kiladjian, J. J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L*., et al.* (2012). JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med *366*, 787-798.

Kuter, D. J., Bain, B., Mufti, G., Bagg, A., and Hasserjian, R. P. (2007). Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol *139*, 351-362.

Passamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Cazzola, M., and Tefferi, A. (2010). Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood *116*, 2857-2858.

Passamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M*., et al.* (2010). A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood *115*, 1703-1708.

Reilly, J. T., McMullin, M. F., Beer, P. A., Butt, N., Conneally, E., Duncombe, A., Green, A. R., Michaeel, N. G., Gilleece, M. H., Hall, G. W*., et al.* (2012). Guideline for the diagnosis and management of myelofibrosis. Br J Haematol *158*, 453-471.

Tefferi, A. (2011). How I treat myelofibrosis. Blood *117*, 3494-3504.

Thiele, J., Kvasnicka, H. M., Tefferi, A., Barosi, G., Orazi, A., and Vardiman, J.W. (2008). Primary myelofibrosis. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Press, Geneva, Switzerland. p44-47.

Thiele, J., Kvasnicka, H. M., Orazi, A., Tefferi, A., and Birgegard, G.(2008). Polycythaemia vera. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Press, Geneva, Switzerland. p40-43.

Thiele, J., Kvasnicka, H. M., Orazi, A., Tefferi, A., and Gisslinger, H. (2008). Essential thrombocythaemia. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Press, Geneva, Switzerland. p48-50.

Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T*., et al.* (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med *366*, 799-807.